Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Huang et al	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period	Vaccine,Volume 39, Issue 33, 30 July 2021, Pages 4641-4650 , doi.org/10.1016/j.vaccine.2021.06.066	2021	HIV	Carter Lee, Vineeta Gulati, Faruk Sinangil
Pitisuttithum et al	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.	Lancet HIV. 2020 Feb 6. pii: S2352-3018(19)30406-0. doi: 10.1016/S2352-3018(19)30406-0.	2020	HIV	Don Francis, Carter Lee, and Faruk Sinangil
Easterhoff et al	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.	J Virol. 2020 Jan 31;94(4). pii: e01120-19. doi: 10.1128/JVI.01120-19.	2020	HIV	Faruk Sinangil
Easterhoff et al	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.	JCI Insight. 2020 Jan 30;5(2). pii: 131437. doi: 10.1172/jci.insight.131437.	2020	HIV	Faruk Sinangil, Keith Higgins
Meza et al	Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine.	AIDS. 2020 Jan 1;34(1):25-32. doi: 10.1097/QAD.0000000000002401	2020	HIV	Faruk Sinangil

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Rouphael et al	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.	J Clin Invest. 2019 Nov 1;129(11):4769-4785. doi: 10.1172/JCI128699	2019	HIV	Faruk Sinangil, Don Francis
Pantaleo et al	Co-administration of HIV Env protein with DNA and/or NYVAC vaccines in humans results in earlier and potent generation of anti-Env antibody response.	The Lancet HIV. 2019; 6(11): PE737-E749. doi: 10.1016/S2352-3018(19)30262-0	2019	HIV	Faruk Sinangil, Don Francis, Carter Lee
Gray et al	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.	Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.	2019	HIV	Don Francis
Mesa et al	Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens.	PLoS One. 2019 Apr 10;14(4):e0213409. doi: 10.1371/journal.pone.0213409. eCollection 2019	2019	HIV	Faruk Sinangil, Don Francis
Akapirat et al	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.	PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018.	2018	HIV	Faruk Sinangil
Balasubramanian et a	Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.	Sci Rep. 2018 Jan 11;8(1):542. doi: 10.1038/s41598-017-18863-0.	2018	HIV	Ian Francis

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Gilbert et al	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women	PLOS ONE 12(5): e0176428. https://doi.org/10.1371/journal.pone.0176428	2017	HIV	Don Francis
Rerks-Ngarm et al	Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial	J Infect Dis. 2017 Feb 21. doi: 10.1093/infdis/jix099.	2017	HIV	Don Francis
Balasubramanian et al	Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination	Vaccine. 2017 Feb 6. pii: S0264-410X(17)30089-0. doi: 10.1016/j.vaccine.2016.11.107.	2017	HIV	Don Francis
Easterhoff et al	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial	PLoS Pathog 13(2): e1006182. doi:10.1371/journal.ppat.1006182	2017	HIV	Don Francis
Karnasuta et al	Comparison of Antibody Responses Induced by RV144, VAX003 and VAX004 Vaccination Regimens.	AIDS Res Hum Retroviruses. 2016 Dec 22. doi: 10.1089/AID.2016.0204	2016	HIV	Keith Higgins

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Luo et al	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.	JCI Insight. 2016 Dec 8;1(20):e88522. DOI: 10.1172/jci.insight.88522	2016	HIV	Don Francis, Carter Lee, and Faruk Sinangil
Mahan et al	Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination	PLoS Pathog 12(3): e1005456. doi: 10.1371/journal.ppat.1005456	2016	HIV	Don Francis
Karasavvas et al	IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.	AIDS Research and Human Retroviruses. 2015;31(11):1178-1186. doi:10.1089/aid.2015.0034.	2015	HIV	Don Francis, Carter Lee, and Faruk Sinangil
Wiehe et al	Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.	Immunity. 2014;41(6):909-918. doi:10.1016/j.immuni.2014.11.014.	2014	HIV	Faruk Sinangil
Dell et al	Field evaluation of a camera-based mobile health system in low-resource settings.	In Proceedings of the 16th international conference on Human-computer interaction with mobile devices & services (MobileHCI '14). ACM, New York, NY, USA, 33-42. DOI=10.1145/2628363.2628366	2014	mHealth	Faruk Sinangil

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Chung et al	Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines	Sci Transl Med 19 March 2014: (6/ 228: 228-38) Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007736	2014	HIV	Faruk Sinangil
Arita et al	Chapter 21. Variola Viruses. In: Manual of Security Sensitive Microbes and Toxins.	Ed. Don Liu. CRC Press 2014.	2014	Small pox	Don Francis
Arita et al	Is it time to destroy the smallpox virus?	Science 29 August 2014: 1010. DOI:10.1126/science.345.6200.1010-a	2014	Small pox	Don Francis
Francis et al	Global Vaccine Supply - the increasing role of manufacturers from middle income countries	Vaccine 32: 5259-5265; 2014	2014	General	Faruk Sinangil
Penezina et al	Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants	Clin Vaccine Immunol March 2014 vol. 21 no. 3 391-398	2014	HIV	Don Francis
Yates et al	Vaccine-Induced Env V1/V2 IgG3 Correlate with Lower HIV-Infection Risk and Declines Soon After Vaccination	Sci Transl Med 19 March 2014: Vol. 6, Issue 228, p. 228ra39 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007730	2014	HIV	Don Francis, Carter Lee, and Faruk Sinangil

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Dubin et al	Closing the circle: a thirty-year retrospective on the AIDS/blood epidemic.	Transfusion, 2013, Vol 53 (9), DOI: 10.1111/trf.12374	2013	HIV	Faruk Sinangil
Gottardo et al	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial	PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013.	2013	HIV	Don Francis
Alam et al	Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.	J Virol. 2013 Feb;87(3):1554-68. doi: 10.1128/JVI.00718-12. Epub 2012 Nov 21.	2013	HIV	Don Francis
Liao et al	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2	Immunity - 24 January 2013 (Vol. 38, Issue 1, pp. 176-186). doi: 10.1016/j.immuni.2012.11.011	2013	HIV	Faruk Sinangil
O'Rourke et al	Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.	J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29.	2012	HIV	Faruk Sinangil

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Francis	Deadly AIDS policy failure by the highest levels of the US government: a personal look back 30 years later for lessons to respond better to future epidemics.	Journal of Public Health Policy (2012) 33, 290–300. doi:10.1057/jphp.2012.14	2012	HIV	Don Francis
Francis	Protecting the public's health: remove the political constraints that hamper the Centers for Disease Control and Prevention.	AIDS. 2012 Jun 1;26(9):1175-6. doi:10.1097/QAD.0b013e32835392dd	2012	General	Faruk Sinangil
Karasavvas et al	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120	AIDS Research and Human Retroviruses. November 2012, 28(11): 1444-1457. doi: 10.1089/aid.2012.0103	2012	HIV	Faruk Sinangil
Mahoney et al	Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil.	Vaccine, Volume 30, Issue 32, 6 July 2012, Pages 4892-4896, ISSN 0264-410X, 10.1016/j.vaccine.2012.02.064.	2012	Dengue	Don Francis
Montefiori et al	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials.	J Infect Dis. (2012) 206(3): 431-441. doi:10.1093/infdis/jis367	2012	HIV	Don Francis

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
O'Rourke et al	Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies.	J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29.	2012	HIV	Faruk Sinangil
Rerks-Ngarm et al	Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E.	J Infect Dis. first published online July 26, 2012 doi:10.1093/infdis/jis478	2012	HIV	Faruk Sinangil
Robb et al	Risk behavior and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.	The Lancet Infectious Diseases, Volume 12, Issue 7, Pages 531 - 537, July 2012. DOI: 10.1016/S1473-3099(12)70088-9	2012	HIV	Faruk Sinangil
Alam et al	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen is Enhanced by a gp120 N-terminal Deletion	J. Virol. February 2013 87:3 1554-1568; published ahead of print 21 November 2012, doi:10.1128/JVI.00718-12	2012	HIV	Don Francis

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Stephenson et al	Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials.	J Infect Dis. (2012) 205(12): 1806-1810 first published online April 5, 2012 doi:10.1093/infdis/jis285	2012	HIV	Don Francis
Arita et al	Safe landing for global polio eradication: A Perspective.	Vaccine. 29 (2011) 8827-34. doi:10.1016/j.vaccine.2011.09.059	2011	Polio	Don Francis
Barouch et al	International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.	Vaccine. 2011 Jul 18;29 (32):5203-9. Epub 2011 May 25. doi:10.1016/j.vaccine.2011.05.025	2011	HIV	Don Francis
Bonsignori et al	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors.	J Virol. 2011 Oct;85(19):9998-10009. Epub 2011 Jul 27. doi:10.1128/JVI.05045-11	2011	HIV	Faruk Sinangil
Francis et al	WHO Influenza vaccine technology transfer initiative: Role and activities of the Technical Advisory Group.	Vaccine 295 (2011) A45-A47. doi:10.1016/j.vaccine.2011.02.078	2011	Influenza	Faruk Sinangil
Mahoney et al	Dengue vaccines regulatory pathways: A report on two meetings with regulators of developing countries.	PLoS Med 8(2): e1000418. Published February 22, 2011. doi:10.1371/journal.pmed.1000418.	2011	Dengue	Faruk Sinangil

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Bonsignori et al	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.	J Virol. 2011 Oct;85(19):9998-10009. doi: 10.1128/JVI.05045-11. Epub 2011 Jul 27.	2011	HIV	Faruk Sinangil
Barouch et al	International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.	Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25.	2011	HIV	Faruk Sinangil
Perez-Losada et al	Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand.	PLoS One. 2011 Mar 10;6(3):e16902. doi:10.1371/journal.pone.0016902	2011	HIV	Faruk Sinangil
Pitisuttihum et al	Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand.	PLoS Vol 6, Issue 12, e27837, December 2011. doi:10.1371/journal.pone.0027837	2011	HIV	Don Francis
MOPH-TAVEG	Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148).	Vaccine 29 (2011) 4285-4292. doi:10.1016/j.vaccine.2011.03.014	2011	HIV	Don Francis
Francis	Successes and failures: Worldwide vaccine development and application.	Biologicals. 2010 Sep;38(5):523-8. Epub 2010 Aug 4. Review. doi:10.1016/j.biologicals.2010.06.003	2010	General	Faruk Sinangil

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Francis et al	The manufacture and supply of dengue vaccine.	Occasional Paper, Pediatric Dengue Vaccine Initiative, International Vaccine Institute, December 2010.	2010	Dengue	Faruk Sinangil
Gilbert et al	Magnitude and breadth of a non-protective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.	J Infect Dis 202 (4): 595-605 (2010). doi: 10.1086/654816	2010	HIV	
O'Rourke et al	Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.	J Virol. 2010 Nov;84(21):11200-9. doi:10.1128/JVI.00790-10	2010	HIV	
Perez-Losada et al	Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America.	Mol Biol Evol 27(2):417-25 (2010). doi: 10.1093/molbev/msp254	2010	HIV	
Smith et al	Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.	PLoS One 5(8): e12076 (2010). Doi:1371/journal.pone.0012076	2010	HIV	
O'Rourke et al	Novel ring structure in the gp41 trimer of human deficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies.	J Virol. 83(15):7728-38 (2009). doi:10.1128/JVI.00688-09	2009	HIV	
Perez-Losada et al	Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial.	Retrovirology 6:67 (2009). doi:10.1186/1742-4690-6-67	2009	HIV	

Authors - Short	Title	Publication	Year	Field	GSID Author(s)
Rerks-Ngarm et al	Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.	N Engl J Med. 2009 Dec 3;361(23):2209-20. Epub 2009 Oct 20. doi:10.1056/NEJMoa0908492	2009	HIV	
Pitisuttihum et al	Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand.	J Med Assoc Thai. 2007 Nov;90(11):2442-8.	2007	HIV	
Jobes et al	High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV-1 infections from a Phase 3 vaccine efficacy trial.	AIDS Res Hum Retroviruses 22 (10):1014-21 (2006). doi:10.1089/aid.2006.22.1014	2006	HIV	
Jobes et al	Longitudinal population analysis of dual infection with recombination in two strains of HIV-1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial.	AIDS Res Hum Retroviruses 22 (10): 968-78 (2006). doi: 10.1089/aid.2006.22.968	2006	HIV	